1
|
Nakaji P, Brachman D, Smith K, Thomas T, Dardis C, Pinnaduwage D, Wallstrom G, Rogers C, Youssef E. Resection and Surgically Targeted Brain Brachytherapy Without and With Systemic Therapy for Locally Recurrent GBM. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1592] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
2
|
Bell E, McElroy J, Fleming J, Timmers C, Chakraborty A, Salavaggione A, Chang S, Shaw E, Aldape K, Brachman D, Schultz C, Shih H, Curtis M, Hunter G, Murtha A, Zhang P, Won M, Mehta M, Chakravarti A. A Mutation and Prognostic Biomarker Study in Grade II and III Gliomas Utilizing a Combined Cohort of NRG Oncology/RTOG 9802 and 9813. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
3
|
Bell E, Zhang P, Buckner J, Chang S, Salavaggione A, Brachman D, Lee R, Murtha A, Brown P, Schultz C, Malone S, Mehta M, Pugh S, Chakravarti A. Treatment Responses and Survival in IDH1-Mutant Grade II and III Gliomas in NRG Oncology/RTOG 9802 and 9813. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2015.10.041] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
4
|
Brachman D, Nakaji P, Dardis C, Sorensen S, Thomas T, Smith K, Sanai N, Youssef E, McBride H. AT-10 * SURGERY (S) AND PERMANENT INTRAOPERATIVE BRACHYTHERAPY (BT) IMPROVES TIME TO PROGRESSION OF RECURRENT INTRACRANIAL NEOPLASMS: A REPORT OF 27 CASES USING A MODULAR, BIOCOMPATIBLE CARRIER AND REAL-TIME DOSIMETRIC PLANNING. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou237.10] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
5
|
Bell EH, Pugh S, Gilbert M, Mehta M, Klimowicz A, Magliocco A, Bredel M, Robe P, Grosu A, Stupp R, Curran W, Corn B, Brown P, Glass J, Souhami L, Jeffrey Lee R, Brachman D, Deutsch M, Won M, Chakravarti A. BI-12 * RTOG 0525 RECURSIVE PARTITIONING ANALYSIS BASED ON CLINICAL AND PROTEIN BIOMARKER PARAMETERS. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou239.12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
6
|
Zhou R, Scheurer M, Vera-Bolanos E, Gilbert M, Bondy M, Sulman E, Hilsenbeck S, Wendland M, Brachman D, Roof K, Komaki R, Deutsch M, Andrews D, Anderson B, Lee RJ, Pugh S, Armstrong T. CN-21 * RISK MODELING FOR TEMOZOLOMIDE (TMZ)-MYELOTOXICITY IN PATIENTS WITH GLIOBLASTOMA TREATED ON RTOG 0825. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou243.21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
Cairncross G, Wang M, Jenkins R, Shaw E, Giannini C, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Huse JT, Mehta M. BENEFICIAL OUTCOMES AFTER PCV PLUS RT IN OLIGODENDROGLIAL TUMORS ARE ASSOCIATED WITH DETECTION OR RISK OF AN IDH MUTATION. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou209.11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
8
|
Ambady P, Holdhoff M, Ferrigno C, Grossman S, Anderson MD, Liu D, Conrad C, Penas-Prado M, Gilbert MR, Yung AWK, de Groot J, Aoki T, Nishikawa R, Sugiyama K, Nonoguchi N, Kawabata N, Mishima K, Adachi JI, Kurisu K, Yamasaki F, Tominaga T, Kumabe T, Ueki K, Higuchi F, Yamamoto T, Ishikawa E, Takeshima H, Yamashita S, Arita K, Hirano H, Yamada S, Matsutani M, Apok V, Mills S, Soh C, Karabatsou K, Arimappamagan A, Arya S, Majaid M, Somanna S, Santosh V, Schaff L, Armentano F, Harrison C, Lassman A, McKhann G, Iwamoto F, Armstrong T, Yuan Y, Liu D, Acquaye A, Vera-Bolanos E, Diefes K, Heathcock L, Cahill D, Gilbert M, Aldape K, Arrillaga-Romany I, Ruddy K, Greenberg S, Nayak L, Avgeropoulos N, Avgeropoulos G, Riggs G, Reilly C, Banerji N, Bruns P, Hoag M, Gilliland K, Trusheim J, Bekaert L, Borha A, Emery E, Busson A, Guillamo JS, Bell M, Harrison C, Armentano F, Lassman A, Connolly ES, Khandji A, Iwamoto F, Blakeley J, Ye X, Bergner A, Dombi E, Zalewski C, Follmer K, Halpin C, Fayad L, Jacobs M, Baldwin A, Langmead S, Whitcomb T, Jennings D, Widemann B, Plotkin S, Brandes AA, Mason W, Pichler J, Nowak AK, Gil M, Saran F, Revil C, Lutiger B, Carpentier AF, Milojkovic-Kerklaan B, Aftimos P, Altintas S, Jager A, Gladdines W, Lonnqvist F, Soetekouw P, van Linde M, Awada A, Schellens J, Brandsma D, Brenner A, Sun J, Floyd J, Hart C, Eng C, Fichtel L, Gruslova A, Lodi A, Tiziani S, Bridge CA, Baldock A, Kumthekar P, Dilfer P, Johnston SK, Jacobs J, Corwin D, Guyman L, Rockne R, Sonabend A, Cloney M, Canoll P, Swanson KR, Bromberg J, Schouten H, Schaafsma R, Baars J, Brandsma D, Lugtenburg P, van Montfort C, van den Bent M, Doorduijn J, Spalding A, LaRocca R, Haninger D, Saaraswat T, Coombs L, Rai S, Burton E, Burzynski G, Burzynski S, Janicki T, Marszalek A, Burzynski S, Janicki T, Burzynski G, Marszalek A, Cachia D, Smith T, Cardona AF, Mayor LC, Jimenez E, Hakim F, Yepes C, Bermudez S, Useche N, Asencio JL, Mejia JA, Vargas C, Otero JM, Carranza H, Ortiz LD, Cardona AF, Ortiz LD, Jimenez E, Hakim F, Yepes C, Useche N, Bermudez S, Asencio JL, Carranza H, Vargas C, Otero JM, Bartels C, Quintero A, Restrepo CE, Gomez S, Bernal-Vaca L, Lema M, Cardona AF, Ortiz LD, Useche N, Bermudez S, Jimenez E, Hakim F, Yepes C, Mejia JA, Bernal-Vaca L, Restrepo CE, Gomez S, Quintero A, Bartels C, Carranza H, Vargas C, Otero JM, Carlo M, Omuro A, Grommes C, Kris M, Nolan C, Pentsova E, Pietanza M, Kaley T, Carrabba G, Giammattei L, Draghi R, Conte V, Martinelli I, Caroli M, Bertani G, Locatelli M, Rampini P, Artoni A, Carrabba G, Bertani G, Cogiamanian F, Ardolino G, Zarino B, Locatelli M, Caroli M, Rampini P, Chamberlain M, Raizer J, Soffetti R, Ruda R, Brandsma D, Boogerd W, Taillibert S, Le Rhun E, Jaeckle K, van den Bent M, Wen P, Chamberlain M, Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Kerloeguen Y, Guijarro A, Cloughsey T, Choi JH, Hong YK, Conrad C, Yung WKA, deGroot J, Gilbert M, Loghin M, Penas-Prado M, Tremont I, Silberman S, Picker D, Costa R, Lycette J, Gancher S, Cullen J, Winer E, Hochberg F, Sachs G, Jeyapalan S, Dahiya S, Stevens G, Peereboom D, Ahluwalia M, Daras M, Hsu M, Kaley T, Panageas K, Curry R, Avila E, Fuente MDL, Omuro A, DeAngelis L, Desjardins A, Sampson J, Peters K, Ranjan T, Vlahovic G, Threatt S, Herndon J, Boulton S, Lally-Goss D, McSherry F, Friedman A, Friedman H, Bigner D, Gromeier M, Prust M, Kalpathy-Cramer J, Poloskova P, Jafari-Khouzani K, Gerstner E, Dietrich J, Fabi A, Villani V, Vaccaro V, Vidiri A, Giannarelli D, Piludu F, Anelli V, Carapella C, Cognetti F, Pace A, Flowers A, Flowers A, Killory B, Furuse M, Miyatake SI, Kawabata S, Kuroiwa T, Garciarena P, Anderson MD, Hamilton J, Schellingerhout D, Fuller GN, Sawaya R, Gilbert MR, Gilbert M, Pugh S, Won M, Blumenthal D, Vogelbaum M, Aldape K, Colman H, Chakravarti A, Jeraj R, Dignam J, Armstrong T, Wefel J, Brown P, Jaeckle K, Schiff D, Brachman D, Werner-Wasik M, Tremont-Lukats I, Sulman E, Mehta M, Gill B, Yun J, Goldstein H, Malone H, Pisapia D, Sonabend AM, Mckhann GK, Sisti MB, Sims P, Canoll P, Bruce JN, Girvan A, Carter G, Li L, Kaltenboeck A, Chawla A, Ivanova J, Koh M, Stevens J, Lahn M, Gore M, Hariharan S, Porta C, Bjarnason G, Bracarda S, Hawkins R, Oudard S, Zhang K, Fly K, Matczak E, Szczylik C, Grossman R, Ram Z, Hamza M, O'Brien B, Mandel J, DeGroot J, Han S, Molinaro A, Berger M, Prados M, Chang S, Clarke J, Butowski N, Hashimoto N, Chiba Y, Tsuboi A, Kinoshita M, Hirayama R, Kagawa N, Oka Y, Oji Y, Sugiyama H, Yoshimine T, Hawkins-Daarud A, Jackson PR, Swanson KR, Sarmiento JM, Ly D, Jutla J, Ortega A, Carico C, Dickinson H, Phuphanich S, Rudnick J, Patil C, Hu J, Iglseder S, Nowosielski M, Nevinny-Stickel M, Stockhammer G, Jain R, Poisson L, Scarpace L, Mikkelsen T, Kirby J, Freymann J, Hwang S, Gutman D, Jaffe C, Brat D, Flanders A, Janicki T, Burzynski S, Burzynski G, Marszalek A, Jiang C, Wang H, Jo J, Williams B, Smolkin M, Wintermark M, Shaffrey M, Schiff D, Juratli T, Soucek S, Kirsch M, Schackert G, Kakkar A, Kumar S, Bhagat U, Kumar A, Suri A, Singh M, Sharma M, Sarkar C, Suri V, Kaley T, Barani I, Chamberlain M, McDermott M, Raizer J, Rogers L, Schiff D, Vogelbaum M, Weber D, Wen P, Kalita O, Vaverka M, Hrabalek L, Zlevorova M, Trojanec R, Hajduch M, Kneblova M, Ehrmann J, Kanner AA, Wong ET, Villano JL, Ram Z, Khatua S, Fuller G, Dasgupta S, Rytting M, Vats T, Zaky W, Khatua S, Sandberg D, Foresman L, Zaky W, Kieran M, Geoerger B, Casanova M, Chisholm J, Aerts I, Bouffet E, Brandes AA, Leary SES, Sullivan M, Bailey S, Cohen K, Mason W, Kalambakas S, Deshpande P, Tai F, Hurh E, McDonald TJ, Kieran M, Hargrave D, Wen PY, Goldman S, Amakye D, Patton M, Tai F, Moreno L, Kim CY, Kim T, Han JH, Kim YJ, Kim IA, Yun CH, Jung HW, Koekkoek JAF, Reijneveld JC, Dirven L, Postma TJ, Vos MJ, Heimans JJ, Taphoorn MJB, Koeppen S, Hense J, Kong XT, Davidson T, Lai A, Cloughesy T, Nghiemphu PL, Kong DS, Choi YL, Seol HJ, Lee JI, Nam DH, Kool M, Jones DTW, Jager N, Northcott PA, Pugh T, Hovestadt V, Markant S, Esparza LA, Bourdeaut F, Remke M, Taylor MD, Cho YJ, Pomeroy SL, Schuller U, Korshunov A, Eils R, Wechsler-Reya RJ, Lichter P, Pfister SM, Krel R, Krutoshinskaya Y, Rosiello A, Seidman R, Kowalska A, Kudo T, Hata Y, Maehara T, Kumthekar P, Bridge C, Patel V, Rademaker A, Helenowski I, Mrugala M, Rockhill J, Swanson K, Grimm S, Raizer J, Meletath S, Bennett M, Nestor VA, Fink KL, Lee E, Reardon D, Schiff D, Drappatz J, Muzikansky A, Hammond S, Grimm S, Norden A, Beroukhim R, McCluskey C, Chi A, Batchelor T, Smith K, Gaffey S, Gerard M, Snodgras S, Raizer J, Wen P, Leeper H, Johnson D, Lima J, Porensky E, Cavaliere R, Lin A, Liu J, Evans J, Leuthardt E, Dacey R, Dowling J, Kim A, Zipfel G, Grubb R, Huang J, Robinson C, Simpson J, Linette G, Chicoine M, Tran D, Liubinas SV, D'Abaco GM, Moffat B, Gonzales M, Feleppa F, Nowell CJ, Gorelick A, Drummond KJ, Morokoff AP, O'Brien TJ, Kaye AH, Loghin M, Melhem-Bertrandt A, Penas-Prado M, Zaidi T, Katz R, Lupica K, Stevens G, Ly I, Hamilton S, Rostomily R, Rockhill J, Mrugala M, Mandel J, Yust-Katz S, de Groot J, Yung A, Gilbert M, Burzynski S, Janicki T, Burzynski G, Marszalek A, Pachow D, Kliese N, Kirches E, Mawrin C, McNamara MG, Lwin Z, Jiang H, Chung C, Millar BA, Sahgal A, Laperriere N, Mason WP, Megyesi J, Salehi F, Merker V, Slusarz K, Muzikansky A, Francis S, Plotkin S, Mishima K, Adachi JI, Suzuki T, Uchida E, Yanagawa T, Watanabe Y, Fukuoka K, Yanagisawa T, Wakiya K, Fujimaki T, Nishikawa R, Moiyadi A, Kannan S, Sridhar E, Gupta T, Shetty P, Jalali R, Alshami J, Lecavalier-Barsoum M, Guiot MC, Tampieri D, Kavan P, Muanza T, Nagane M, Kobayashi K, Takayama N, Shiokawa Y, Nakamura H, Makino K, Hideo T, Kuroda JI, Shinojima N, Yano S, Kuratsu JI, Nambudiri N, Arrilaga I, Dunn I, Folkerth R, Chi S, Reardon D, Nayak L, Omuro A, DeAngelis L, Robins HI, Govindan R, Gadgeel S, Kelly K, Rigas J, Reimers HJ, Peereboom D, Rosenfeld S, Garst J, Ramnath N, Wing P, Zheng M, Urban P, Abrey L, Wen P, Nayak L, DeAngelis LM, Wen PY, Brandes AA, Soffietti R, Peereboom DM, Lin NU, Chamberlain M, Macdonald D, Galanis E, Perry J, Jaeckle K, Mehta M, Stupp R, van den Bent M, Reardon DA, Norden A, Hammond S, Drappatz J, Phuphanich S, Reardon D, Wong E, Plotkin S, Lesser G, Raizer J, Batchelor T, Lee E, Kaley T, Muzikansky A, Doherty L, LaFrankie D, Ruland S, Smith K, Gerard M, McCluskey C, Wen P, Norden A, Schiff D, Ahluwalia M, Lesser G, Nayak L, Lee E, Muzikansky A, Dietrich J, Smith K, Gaffey S, McCluskey C, Ligon K, Reardon D, Wen P, Bush NAO, Kesari S, Scott B, Ohno M, Narita Y, Miyakita Y, Arita H, Matsushita Y, Yoshida A, Fukushima S, Ichimura K, Shibui S, Okamura T, Kaneko S, Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V, Lamy T, Gressin R, Choquet S, Soubeyran P, Maire JP, Benouaich-Amiel A, Lebouvier-Sadot S, Gyan E, Barrie M, del Rio MS, Gonzalez-Aguilar A, Houllier C, Tanguy ML, Hoang-Xuan K, Omuro A, Abrey L, Raizer J, Paleologos N, Forsyth P, DeAngelis L, Kaley T, Louis D, Cairncross JG, Matasar M, Mehta J, Grimm S, Moskowitz C, Sauter C, Opinaldo P, Torcuator R, Ortiz LD, Cardona AF, Hakim F, Jimenez E, Yepes C, Useche N, Bermudez S, Mejia JA, Asencio JL, Carranza H, Vargas C, Otero JM, Lema M, Pace A, Villani V, Fabi A, Carapella CM, Patel A, Allen J, Dicker D, Sheehan J, El-Deiry W, Glantz M, Tsyvkin E, Rauschkolb P, Pentsova E, Lee M, Perez A, Norton J, Uschmann H, Chamczuck A, Khan M, Fratkin J, Rahman R, Hempfling K, Norden A, Reardon DA, Nayak L, Rinne M, Doherty L, Ruland S, Rai A, Rifenburg J, LaFrankie D, Wen P, Lee E, Ranjan T, Peters K, Vlahovic G, Friedman H, Desjardins A, Reveles I, Brenner A, Ruda R, Bello L, Castellano A, Bertero L, Bosa C, Trevisan E, Riva M, Donativi M, Falini A, Soffietti R, Saran F, Chinot OL, Henriksson R, Mason W, Wick W, Nishikawa R, Dahr S, Hilton M, Garcia J, Cloughesy T, Sasaki H, Nishiyama Y, Yoshida K, Hirose Y, Schwartz M, Grimm S, Kumthekar P, Fralin S, Rice L, Drawz A, Helenowski I, Rademaker A, Raizer J, Schwartz K, Chang H, Nikolai M, Kurniali P, Olson K, Pernicone J, Sweeley C, Noel M, Sharma M, Gupta R, Suri V, Singh M, Sarkar C, Shibahara I, Sonoda Y, Saito R, Kanamori M, Yamashita Y, Kumabe T, Watanabe M, Suzuki H, Watanabe T, Ishioka C, Tominaga T, Shih K, Chowdhary S, Rosenblatt P, Weir AB, Shepard G, Williams JT, Shastry M, Hainsworth JD, Singer S, Riely GJ, Kris MG, Grommes C, Sanders MWCB, Arik Y, Seute T, Robe PAJT, Leijten FSS, Snijders TJ, Sturla L, Culhane JJ, Donahue J, Jeyapalan S, Suchorska B, Jansen N, Wenter V, Eigenbrod S, Schmid-Tannwald C, Zwergal A, Niyazi M, Bartenstein P, Schnell O, Kreth FW, LaFougere C, Tonn JC, Taillandier L, Wittwer B, Blonski M, Faure G, De Carvalho M, Le Rhun E, Tanaka K, Sasayama T, Nishihara M, Mizukawa K, Kohmura E, Taylor S, Newell K, Graves L, Timmer M, Cramer C, Rohn G, Goldbrunner R, Turner S, Gergel T, Lacroix M, Toms S, Ueki K, Higuchi F, Sakamoto S, Kim P, Salgado MAV, Rueda AG, Urzaiz LL, Villanueva MG, Millan JMS, Cervantes ER, Pampliega RA, de Pedro MDA, Berrocal VR, Mena AC, van Zanten SV, Jansen M, van Vuurden D, Huisman M, Hoekstra O, van Dongen G, Kaspers GJ, Schlamann A, von Bueren AO, Hagel C, Kramm C, Kortmann RD, Muller K, Friedrich C, Muller K, von Hoff K, Kwiecien R, Pietsch T, Warmuth-Metz M, Gerber NU, Hau P, Kuehl J, Kortmann RD, von Bueren AO, Rutkowski S, von Bueren AO, Friedrich C, von Hoff K, Kwiecien R, Muller K, Pietsch T, Warmuth-Metz M, Kuehl J, Kortmann RD, Rutkowski S, Walker J, Tremont I, Armstrong T, Wang H, Jiang C, Wang H, Jiang C, Warren P, Robert S, Lahti A, White D, Reid M, Nabors L, Sontheimer H, Wen P, Yung A, Mellinghoff I, Lamborn K, Ramkissoon S, Cloughesy T, Rinne M, Omuro A, DeAngelis L, Gilbert M, Chi A, Batchelor T, Colman H, Chang S, Nayak L, Massacesi C, DiTomaso E, Prados M, Reardon D, Ligon K, Wong ET, Elzinga G, Chung A, Barron L, Bloom J, Swanson KD, Elzinga G, Chung A, Wong ET, Wu W, Galanis E, Wen P, Das A, Fine H, Cloughesy T, Sargent D, Yoon WS, Yang SH, Chung DS, Jeun SS, Hong YK, Yust-Katz S, Milbourne A, Diane L, Gilbert M, Armstrong T, Zaky W, Weinberg J, Fuller G, Ketonen L, McAleer MF, Ahmed N, Khatua S, Zaky W, Olar A, Stewart J, Sandberg D, Foresman L, Ketonen L, Khatua S. NEURO/MEDICAL ONCOLOGY. Neuro Oncol 2013; 15:iii98-iii135. [PMCID: PMC3823897 DOI: 10.1093/neuonc/not182] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/14/2023] Open
|
9
|
Adachi K, Sasaki H, Nagahisa S, Yoshida K, Hattori N, Nishiyama Y, Kawase T, Hasegawa M, Abe M, Hirose Y, Alentorn A, Marie Y, Poggioli S, Alshehhi H, Boisselier B, Carpentier C, Mokhtari K, Capelle L, Figarella-Branger D, Hoang-Xuan K, Sanson M, Delattre JY, Idbaih A, Yust-Katz S, Anderson M, Olar A, Eterovic A, Ezzeddine N, Chen K, Zhao H, Fuller G, Aldape K, de Groot J, Andor N, Harness J, Lopez SG, Fung TL, Mewes HW, Petritsch C, Arivazhagan A, Somasundaram K, Thennarasu K, Pandey P, Anandh B, Santosh V, Chandramouli B, Hegde A, Kondaiah P, Rao M, Bell R, Kang R, Hong C, Song J, Costello J, Bell R, Nagarajan R, Zhang B, Diaz A, Wang T, Song J, Costello J, Bie L, Li Y, Li Y, Liu H, Luyo WFC, Carnero MH, Iruegas MEP, Morell AR, Figueiras MC, Lopez RL, Valverde CF, Chan AKY, Pang JCS, Chung NYF, Li KKW, Poon WS, Chan DTM, Wang Y, Ng HAK, Chaumeil M, Larson P, Yoshihara H, Vigneron D, Nelson S, Pieper R, Phillips J, Ronen S, Clark V, Omay ZE, Serin A, Gunel J, Omay B, Grady C, Youngblood M, Bilguvar K, Baehring J, Piepmeier J, Gutin P, Vortmeyer A, Brennan C, Pamir MN, Kilic T, Krischek B, Simon M, Yasuno K, Gunel M, Cohen AL, Sato M, Aldape KD, Mason C, Diefes K, Heathcock L, Abegglen L, Shrieve D, Couldwell W, Schiffman JD, Colman H, D'Alessandris QG, Cenci T, Martini M, Ricci-Vitiani L, De Maria R, Larocca LM, Pallini R, de Groot J, Theeler B, Aldape K, Lang F, Rao G, Gilbert M, Sulman E, Luthra R, Eterovic K, Chen K, Routbort M, Verhaak R, Mills G, Mendelsohn J, Meric-Bernstam F, Yung A, MacArthur K, Hahn S, Kao G, Lustig R, Alonso-Basanta M, Chandrasekaran S, Wileyto EP, Reyes E, Dorsey J, Fujii K, Kurozumi K, Ichikawa T, Onishi M, Ishida J, Shimazu Y, Kaur B, Chiocca EA, Date I, Geisenberger C, Mock A, Warta R, Schwager C, Hartmann C, von Deimling A, Abdollahi A, Herold-Mende C, Gevaert O, Achrol A, Gholamin S, Mitra S, Westbroek E, Loya J, Mitchell L, Chang S, Steinberg G, Plevritis S, Cheshier S, Gevaert O, Mitchell L, Achrol A, Xu J, Steinberg G, Cheshier S, Napel S, Zaharchuk G, Plevritis S, Gevaert O, Achrol A, Chang S, Harsh G, Steinberg G, Cheshier S, Plevritis S, Gutman D, Holder C, Colen R, Dunn W, Jain R, Cooper L, Hwang S, Flanders A, Brat D, Hayes J, Droop A, Thygesen H, Boissinot M, Westhead D, Short S, Lawler S, Bady P, Kurscheid S, Delorenzi M, Hegi ME, Crosby C, Faulkner C, Smye-Rumsby T, Kurian K, Williams M, Hopkins K, Faulkner C, Palmer A, Williams H, Wragg C, Haynes HR, Williams M, Hopkins K, Kurian KM, Haynes HR, Crosby C, Williams H, White P, Hopkins K, Williams M, Kurian KM, Ishida J, Kurozumi K, Ichikawa T, Onishi M, Fujii K, Shimazu Y, Oka T, Date I, Jalbert L, Elkhaled A, Phillips J, Chang S, Nelson S, Jensen R, Salzman K, Schabel M, Gillespie D, Mumert M, Johnson B, Mazor T, Hong C, Barnes M, Yamamoto S, Ueda H, Tatsuno K, Aihara K, Jalbert L, Nelson S, Bollen A, Hirst M, Marra M, Mukasa A, Saito N, Aburatani H, Berger M, Chang S, Taylor B, Costello J, Popov S, Mackay A, Ingram W, Burford A, Jury A, Vinci M, Jones C, Jones DTW, Hovestadt V, Picelli S, Wang W, Northcott PA, Kool M, Reifenberger G, Pietsch T, Sultan M, Lehrach H, Yaspo ML, Borkhardt A, Landgraf P, Eils R, Korshunov A, Zapatka M, Radlwimmer B, Pfister SM, Lichter P, Joy A, Smirnov I, Reiser M, Shapiro W, Mills G, Kim S, Feuerstein B, Jungk C, Mock A, Geisenberger C, Warta R, Friauf S, Unterberg A, Herold-Mende C, Juratli TA, McElroy J, Meng W, Huebner A, Geiger KD, Krex D, Schackert G, Chakravarti A, Lautenschlaeger T, Kim BY, Jiang W, Beiko J, Prabhu S, DeMonte F, Lang F, Gilbert M, Aldape K, Sawaya R, Cahill D, McCutcheon I, Lau C, Wang L, Terashima K, Yamaguchi S, Burstein M, Sun J, Suzuki T, Nishikawa R, Nakamura H, Natsume A, Terasaka S, Ng HK, Muzny D, Gibbs R, Wheeler D, Lautenschlaeger T, Juratli TA, McElroy J, Meng W, Huebner A, Geiger KD, Krex D, Schackert G, Chakravarti A, Zhang XQ, Sun S, Lam KF, Kiang KMY, Pu JKS, Ho ASW, Leung GKK, Loebel F, Curry WT, Barker FG, Lelic N, Chi AS, Cahill DP, Lu D, Yin J, Teo C, McDonald K, Madhankumar A, Weston C, Slagle-Webb B, Sheehan J, Patel A, Glantz M, Connor J, Maire C, Francis J, Zhang CZ, Jung J, Manzo V, Adalsteinsson V, Homer H, Blumenstiel B, Pedamallu CS, Nickerson E, Ligon A, Love C, Meyerson M, Ligon K, Mazor T, Johnson B, Hong C, Barnes M, Jalbert LE, Nelson SJ, Bollen AW, Smirnov IV, Song JS, Olshen AB, Berger MS, Chang SM, Taylor BS, Costello JF, Mehta S, Armstrong B, Peng S, Bapat A, Berens M, Melendez B, Mollejo M, Mur P, Hernandez-Iglesias T, Fiano C, Ruiz J, Rey JA, Mock A, Stadler V, Schulte A, Lamszus K, Schichor C, Westphal M, Tonn JC, Unterberg A, Herold-Mende C, Morozova O, Katzman S, Grifford M, Salama S, Haussler D, Nagarajan R, Zhang B, Johnson B, Bell R, Olshen A, Fouse S, Diaz A, Smirnov I, Kang R, Wang T, Costello J, Nakamizo S, Sasayama T, Tanaka H, Tanaka K, Mizukawa K, Yoshida M, Kohmura E, Northcott P, Hovestadt V, Jones D, Kool M, Korshunov A, Lichter P, Pfister S, Otani R, Mukasa A, Takayanagi S, Saito K, Tanaka S, Shin M, Saito N, Ozawa T, Riester M, Cheng YK, Huse J, Helmy K, Charles N, Squatrito M, Michor F, Holland E, Perrech M, Dreher L, Rohn G, Goldbrunner R, Timmer M, Pollo B, Palumbo V, Calatozzolo C, Patane M, Nunziata R, Farinotti M, Silvani A, Lodrini S, Finocchiaro G, Lopez E, Rioscovian A, Ruiz R, Siordia G, de Leon AP, Rostomily C, Rostomily R, Silbergeld D, Kolstoe D, Chamberlain M, Silber J, Roth P, Keller A, Hoheisel J, Codo P, Bauer A, Backes C, Leidinger P, Meese E, Thiel E, Korfel A, Weller M, Saito K, Mukasa A, Nagae G, Nagane M, Aihara K, Takayanagi S, Tanaka S, Aburatani H, Saito N, Salama S, Sanborn JZ, Grifford M, Brennan C, Mikkelsen T, Jhanwar S, Chin L, Haussler D, Sasayama T, Tanaka K, Nakamizo S, Nishihara M, Tanaka H, Mizukawa K, Kohmura E, Schliesser M, Grimm C, Weiss E, Claus R, Weichenhan D, Weiler M, Hielscher T, Sahm F, Wiestler B, Klein AC, Blaes J, Weller M, Plass C, Wick W, Stragliotto G, Rahbar A, Soderberg-Naucler C, Sulman E, Won M, Ezhilarasan R, Sun P, Blumenthal D, Vogelbaum M, Colman H, Jenkins R, Chakravarti A, Jeraj R, Brown P, Jaeckle K, Schiff D, Dignam J, Atkins J, Brachman D, Werner-Wasik M, Gilbert M, Mehta M, Aldape K, Terashima K, Shen J, Luan J, Yu A, Suzuki T, Nishikawa R, Matsutani M, Liang Y, Man TK, Lau C, Trister A, Tokita M, Mikheeva S, Mikheev A, Friend S, Rostomily R, van den Bent M, Erdem L, Gorlia T, Taphoorn M, Kros J, Wesseling P, Dubbink H, Ibdaih A, Sanson M, French P, van Thuijl H, Mazor T, Johnson B, Fouse S, Heimans J, Wesseling P, Ylstra B, Reijneveld J, Taylor B, Berger M, Chang S, Costello J, Prabowo A, van Thuijl H, Scheinin I, van Essen H, Spliet W, Ferrier C, van Rijen P, Veersema T, Thom M, Meeteren ASV, Reijneveld J, Ylstra B, Wesseling P, Aronica E, Kim H, Zheng S, Mikkelsen T, Brat DJ, Virk S, Amini S, Sougnez C, Chin L, Barnholtz-Sloan J, Verhaak RGW, Watts C, Sottoriva A, Spiteri I, Piccirillo S, Touloumis A, Collins P, Marioni J, Curtis C, Tavare S, Weiss E, Grimm C, Schliesser M, Hielscher T, Claus R, Sahm F, Wiestler B, Klein AC, Blaes J, Tews B, Weiler M, Weichenhan D, Hartmann C, Weller M, Plass C, Wick W, Yeung TPC, Al-Khazraji B, Morrison L, Hoffman L, Jackson D, Lee TY, Yartsev S, Bauman G, Zheng S, Fu J, Vegesna R, Mao Y, Heathcock LE, Torres-Garcia W, Ezhilarasan R, Wang S, McKenna A, Chin L, Brennan CW, Yung WKA, Weinstein JN, Aldape KD, Sulman EP, Chen K, Koul D, Verhaak RGW. OMICS AND PROGNSTIC MARKERS. Neuro Oncol 2013; 15:iii136-iii155. [PMCID: PMC3823898 DOI: 10.1093/neuonc/not183] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/21/2023] Open
|
10
|
Ahmed I, Biswas A, Krishnamurthy S, Julka P, Rath G, Back M, Huang D, Gzell C, Chen J, Kastelan M, Gaur P, Wheeler H, Badiyan SN, Robinson CG, Simpson JR, Tran DD, Rich KM, Dowling JL, Chicoine MR, Leuthardt EC, Kim AH, Huang J, Michaelsen SR, Christensen IJ, Grunnet K, Stockhausen MT, Broholm H, Kosteljanetz M, Poulsen HS, Tieu M, Lovblom E, Macnamara M, Mason W, Rodin D, Tai E, Ubhi K, Laperriere N, Millar BA, Menard C, Perkins B, Chung C, Clarke J, Molinaro A, Phillips J, Butowski N, Chang S, Perry A, Costello J, DeSilva A, Rabbitt J, Prados M, Cohen AL, Anker C, Shrieve D, Hall B, Salzman K, Jensen R, Colman H, Farber O, Weinberg U, Palti Y, Fisher B, Chen H, Macdonald D, Lesser G, Coons S, Brachman D, Ryu S, Werner-Wasik M, Bahary JP, Chakravarti A, Mehta M, Gupta T, Nair V, Epari S, Godasastri J, Moiyadi A, Shetty P, Juvekar S, Jalali R, Herrlinger U, Schafer N, Steinbach J, Weyerbrock A, Hau P, Goldbrunner R, Kohnen R, Urbach H, Stummer W, Glas M, Houillier C, Ghesquieres H, Chabrot C, Soussain C, Ahle G, Choquet S, Faurie P, Bay JO, Vargaftig J, Gaultier C, Nicolas-Virelizier E, Hoang-Xuan K, Iskanderani O, Izar F, Benouaich-Amiel A, Filleron T, Moyal E, Iweha C, Jain S, Melian E, Sethi A, Albain K, Shafer D, Emami B, Kong XT, Green S, Filka E, Green R, Yong W, Nghiemphu P, Cloughesy T, Lai A, Mallick S, Biswas A, Roy S, Purkait S, Gupta S, Julka PK, Rath GK, Marosi C, Thaler J, Ay C, Kaider A, Reitter EM, Haselbock J, Preusser M, Flechl B, Zielinski C, Pabinger I, Miyatake SI, Furuse M, Miyata T, Yoritsune E, Kawabata S, Kuroiwa T, Muragaki Y, Maruyama T, Iseki H, Akimoto J, Ikuta S, Nitta M, Maebayashi K, Saito T, Okada Y, Kaneko S, Matsumura A, Kuroiwa T, Karasawa K, Nakazato Y, Kayama T, Nabors LB, Fink KL, Mikkelsen T, Grujicic D, Tarnawski R, Nam DH, Mazurkiewicz M, Salacz M, Ashby L, Thurzo L, Zagonel V, Depenni R, Perry JR, Henslee-Downey J, Picard M, Reardon DA, Nambudiri N, Nayak L, LaFrankie D, Wen P, Ney D, Carlson J, Damek D, Blatchford P, Gaspar L, Kavanagh B, Waziri A, Lillehei K, Reddy K, Chen C, Rashed I, Melian E, Sethi A, Barton K, Anderson D, Prabhu V, Rusch R, Belongia M, Maheshwari M, Firat S, Schiff D, Desjardins A, Cloughesy T, Mikkelsen T, Glantz M, Chamberlain M, Reardon DA, Wen P, Shapiro W, Gopal S, Judy K, Patel S, Mahapatra A, Shan J, Gupta D, Shih K, Bacha JA, Brown D, Garner WJ, Steino A, Schwart R, Kanekal S, Li M, Lopez L, Burris HA, Soderberg-Naucler C, Rahbar A, Stragliotto G, Song AJ, Kumar AMS, Murphy ES, Tekautz T, Suh JH, Recinos V, Chao ST, Spoor J, Korami K, Kloezeman J, Balvers R, Dirven C, Lamfers M, Leenstra S, Sumrall A, Haggstrom D, Crimaldi A, Symanowski J, Giglio P, Asher A, Burri S, Sunkersett G, Khatib Z, Prajapati CM, Magalona EE, Mariano M, Sih IM, Torcuator R, Taal W, Oosterkamp H, Walenkamp A, Beerenpoot L, Hanse M, Buter J, Honkoop A, Boerman D, de Vos F, Jansen R, van der Berkmortel F, Brandsma D, Enting R, Kros J, Bromberg J, van Heuvel I, Smits M, van der Holt R, Vernhout R, van den Bent M, Weinberg U, Farber O, Palti Y, Wick W, Suarez C, Rodon J, Desjardins A, Forsyth P, Gueorguieva I, Cleverly A, Burkholder T, Desaiah D, Lahn M, Zach L, Guez D, Last D, Daniels D, Nissim O, Grober Y, Hoffmann C, Nass D, Talianski A, Spiegelmann R, Cohen Z, Mardor Y. MEDICAL RADIATION THERAPIES. Neuro Oncol 2013; 15:iii75-iii84. [PMCID: PMC3823894 DOI: 10.1093/neuonc/not179] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/21/2023] Open
|
11
|
Allen D, Carlson B, Allen D, Carlson B, Boele F, Zant M, Heine E, Aaronson N, Taphoorn M, Reijneveld J, Heimans J, Klein M, Bradshaw M, Noll K, Ziu M, Weinberg J, Strange C, Turner C, Wefel J, Carlson-Green B, Puig J, Bendel A, Lu Y, Clark K, Conklin H, Merchant T, Klimo P, Panandiker AP, Conklin H, Ashford J, Clark K, Martin-Elbahesh K, Hardy K, Merchant T, Ogg R, Jeha S, Huang L, Zhang H, Correa D, Satagopan J, Baser R, Cheung K, Lin M, Karimi S, Lyo J, DeAngelis L, Orlow I, De Witte E, Satoer D, Erik R, Colle H, Visch-Brink E, Marien P, De Witte E, Marien P, Gehring K, Hoogendoorn P, Sitskoorn M, Gondi V, Mehta M, Pugh S, Tome W, Corn B, Caine C, Kanner A, Rowley H, Kundapur V, Greenspoon J, Konski A, Bauman G, Shi W, Kavadi V, Kachnic L, Driever PH, Soelva V, Rueckriegel S, Bruhn H, Thomale U, Lambourn C, Corbett A, Linville C, Mintz A, Hampson R, Deadwyler S, Peiffer A, Noll K, Weinberg J, Ziu M, Turner C, Strange C, Wefel J, Peters K, Kenjale A, West M, Hornsby W, Herndon J, McSherry F, Desjardins A, Friedman H, Jones L, Peters K, Woodring S, Affronti ML, Threatt S, Lindhorst S, Levacic D, Desjardins A, Ranjan T, Vlahovic G, Friedman A, Friedman H, Resendiz CV, Armstrong TS, Acquaye A, Vera-Bolanos E, Gilbert M, Wefel JS, Turner C, Strange C, Bradshaw M, Noll K, Wefel J, Wefel J, Pugh S, Armstrong T, Gilbert M, Won M, Wendland M, Brachman D, Brown P, Crocker I, Robins HI, Lee RJ, Mehta M, Ziu M, Noll K, Weinberg J, Benveniste R, Turner C, Strange C, Suki D, Wefel J, Caine C, Anderson SK, Harel BT, Brown P, Cerhan JH. NEURO-COGNITIVE. Neuro Oncol 2013. [DOI: 10.1093/neuonc/not181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
12
|
Adachi JI, Totake K, Shirahata M, Mishima K, Suzuki T, Yanagisawa T, Fukuoka K, Nishikawa R, Arimappamagan A, Manoj N, Mahadevan A, Bhat D, Arvinda H, Indiradevi B, Somanna S, Chandramouli B, Petterson SA, Hermansen SK, Dahlrot RH, Hansen S, Kristensen BW, Carvalho F, Jalali S, Singh S, Croul S, Aldape K, Zadeh G, Choi J, Park SH, Khang SK, Suh YL, Kim SP, Lee YS, Kim SH, Coberly S, Samayoa K, Liu Y, Kiaei P, Hill J, Patterson S, Damore M, Dahiya S, Emnett R, Phillips J, Haydon D, Leonard J, Perry A, Gutmann D, Epari S, Ahmed S, Gurav M, Raikar S, Moiyadi A, Shetty P, Gupta T, Jalali R, Georges J, Zehri A, Carlson E, Martirosyan N, Elhadi A, Nichols J, Ighaffari L, Eschbacher J, Feuerstein B, Anderson T, Preul M, Jensen K, Nakaji P, Girardi H, Monville F, Carpentier S, Giry M, Voss J, Jenkins R, Boisselier B, Frayssinet V, Poggionovo C, Catteau A, Mokhtari K, Sanson M, Peyro-Saint-Paul H, Giannini C, Hide T, Nakamura H, Makino K, Yano S, Anai S, Shinojima N, Kuroda JI, Takezaki T, Kuratsu JI, Higuchi F, Matsuda H, Iwata K, Ueki K, Kim P, Kong J, Cooper L, Wang F, Gao J, Teodoro G, Scarpace L, Mikkelsen T, Schniederjan M, Moreno C, Saltz J, Brat D, Cho U, Hong YK, Lee YS, Lober R, Lu L, Gephart MH, Fisher P, Miyazaki M, Nishihara H, Itoh T, Kato M, Fujimoto S, Kimura T, Tanino M, Tanaka S, Nguyen N, Moes G, Villano JL, Nishihara H, Kanno H, Kato Y, Tanaka S, Ohnishi T, Harada H, Ohue S, Kouno S, Inoue A, Yamashita D, Okamoto S, Nitta M, Muragaki Y, Maruyama T, Sawada T, Komori T, Saito T, Okada Y, Omay SB, Gunel JM, Clark VE, Li J, Omay EZE, Serin A, Kolb LE, Hebert RM, Bilguvar K, Ozduman K, Pamir MN, Kilic T, Baehring J, Piepmeier JM, Brennan CW, Huse J, Gutin PH, Yasuno K, Vortmeyer A, Gunel M, Perry A, Pugh S, Rogers CL, Brachman D, McMillan W, Jenrette J, Barani I, Shrieve D, Sloan A, Mehta M, Prabowo A, Iyer A, Veersema T, Anink J, Meeteren ASV, Spliet W, van Rijen P, Ferrier T, Capper D, Thom M, Aronica E, Chharchhodawala T, Sable M, Sharma MC, Sarkar C, Suri V, Singh M, Santosh V, Thota B, Srividya M, Sravani K, Shwetha S, Arivazhagan A, Thennarasu K, Chandramouli B, Hegde A, Kondaiah P, Somasundaram K, Rao M, Santosh V, Kumar VP, Thota B, Shastry A, Arivazhagan A, Thennarasu K, Kondaiah P, Shastry A, Narayan R, Thota B, Somanna S, Thennarasu K, Arivazhagan A, Santosh V, Shastry A, Naz S, Thota B, Thennarasu K, Arivazhagan A, Somanna S, Santosh V, Kondaiah P, Venneti S, Garimella M, Sullivan L, Martinez D, Huse J, Heguy A, Santi M, Thompson C, Judkins A, Voronovich Z, Chen L, Clark K, Walsh M, Mannas J, Horbinski C, Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister SM, Platten M, Weller M, Wick W, Zieman G, Dardis C, Ashby L, Eschbacher J. PATHOLOGY. Neuro Oncol 2013. [DOI: 10.1093/neuonc/not184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
13
|
Cairncross G, Wang M, Jenkins R, Shaw E, Giannini C, Brachman D, Buckner J, Fink K, Mehta M, Curran W. IDH Status Predicts Benefit From PCV With Radiation Therapy in Anaplastic Oligodendroglioma (RTOG 9402). Int J Radiat Oncol Biol Phys 2012. [DOI: 10.1016/j.ijrobp.2012.07.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
14
|
Murphy BA, Chen AY, Curran WJ, Garden AS, Harari PM, Wong SJ, Bellm LA, Schwartz M, Newman J, Adkins D, Hayes DN, Parvathaneni U, Brachman D, Ghabach B, Schneider C, Greenberg M, Abitbol A, Anne PR, Ang KK. Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): Analysis of disparities in care. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.5533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
15
|
Armstrong TS, Wefel JS, Wang M, Won M, Bottomley A, Mendoza TR, Coens C, Werner-Wasik M, Brachman D, Choucair AK, Gilbert MR. Clinical utility of neurocognitive function (NCF), quality of life (QOL), and symptom assessment as prognostic factors for survival and measures of treatment effects on RTOG 0525. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.2016] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
16
|
Chakravarti A, Wang M, Robins H, Guha A, Curren W, Brachman D, Choucair A, Dolled-Filhart M, Lautenschlaeger T, Mehta M. Determinants of Therapeutic Resistance in Glioblastomas: Lessons Learned from RTOG 0211 and Beyond. Int J Radiat Oncol Biol Phys 2010. [DOI: 10.1016/j.ijrobp.2010.07.613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
17
|
Charkravarti A, Wang M, Robins I, Guha A, Curren W, Brachman D, Schultz C, Choucair A, Dolled-Filhart M, Christiansen J, Gustavson M, Molinaro A, Mischel P, Lautenschlaeger T, Dicker A, Mehta M, Phillips CA, Dhulibala S, Hallahan D, Jaboin J, Cardinale FS, Dickey P, Goodrich I, Gorelick J, Sinha R, Dest VM, Chen C, Olsen C, Franklin W, Kleinschmidt-DeMasters B, Kavanagh BD, Lillehei K, Waziri A, Damek D, Gaspar LE, Stauder MC, Laack NN, Link MJ, Pollock BE, Schomberg PJ, Fraser JF, Pannullo SC, Moliterno J, Cobb W, Stieg PE, Vinchon-Petit S, Jarnet D, Michalak S, Lewis A, Benoit JP, Menei P, Desmarais G, Paquette B, Bujold R, Mathieu D, Fortin D, Cuneo KC, Vredenburgh JJ, Sampson JH, Reardon DA, Desjardins A, Peters KL, Kirkpatrick JP, Patel PN, Vyas R, Suryanarayan U, Bhavsar D, Mehta M, Hayhurst C, Monsalves E, Van Prooijen M, Menard C, Zadeh G, Chung C, Burrell K, Lindsey P, Menard C, Zadeh G, Burri SH, Asher AL, Kelly RB, Boltes P, Fraser RW, Dilmanian FA, Rusek A, Desnoyers NR, Park JY, Dane B, Dioszegi I, Hurley SD, O'Banion MK, Tomasi D, Wang R, Meek AG, Sleire L, Wang J, Heggdal J, Pedersen PH, Enger PO, Clump DA, Srinivas R, Wegner RE, Heron DE, Burton SA, Mintz AH, Howard SP, Robins HI, Tome WA, Paravati AJ, Heron DE, Gardner PA, Snyderman C, Ozhasoglu C, Quinn A, Burton SA, Seelman K, Seelman K, Mintz AH, Chang JH, Park YG, Mehta MJ, Patel PN, Vyas RK, Bhavsar DC, Guarnaschelli JN, Imwalle L, Ying J, McPherson C, Warnick R, Breneman J, Khwaja SS, Laack NN, Wetjen NM, Brown PD, Siedow M, Nestler U, Perry J, Huebner A, Chakravarti A, Lautenschlaeger T, Glass J, Andrews D, Werner-Wasik M, Evans J, Lawrence R, Martinez N, Anuradha G, David M, Sara M, Mark L, Ricardo B, Jeff J, Juan H, Kozono D, Zinn P, Ng K, Chen C, Melian E, Prabhu V, Sethi A, Barton K, Anderson D, Rockne RC, Mrugala M, Rockhill J, Swanson KR. Radiation Therapy. Neuro Oncol 2010. [DOI: 10.1093/neuonc/noq116.s15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
Chakravarti A, Wang M, Robins H, Guha A, Curran WJ, Brachman D, Choucair AK, Dolled-Filhart M, Lautenschlaeger T, Mehta MP. Determinants of therapeutic resistance in glioblastomas: Lessons learned from RTOG 0211 and beyond. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.2062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
19
|
Wang M, Cairncross G, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Souhami L, Laperriere N, Mehta M, Curran W. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: Radiation therapy oncology group trial 9402. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e20519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e20519 Background: Radiation Therapy Oncology Group 9402 compared PCV chemotherapy plus radiation therapy (PCV+RT) versus RT alone for anaplastic oligodendroglioma. Here we report 1) longitudinal changes in cognition and quality of life, 2) effects of patient factors and treatments on cognition, quality of life and survival, and 3) prognostic implications of cognition and quality of life. Methods: Cognition was assessed by Mini Mental Status Examination (MMSE) and quality of life by Brain-Quality of Life (B-QOL) by repeat assessments. Scores were analyzed for survivors and within five years of death. Shared parameter models evaluated MMSE/B-QOL with survival. Results: For survivors, MMSE and B-QOL scores were similar longitudinally and between treatments. For those dying within 5 years, MMSE scores were stable initially, while B-QOL scores decreased; both declined rapidly in the last year of life and similarly between arms. In the aggregate, scores decreased over time (P=0.0413 for MMSE; P=0.0016 for B-QOL) and were superior with age < 50 years (P<0.001 for MMSE; P=0.0554 for B-QOL) and KPS 80–100 (P<0.001). Younger age and higher KPS were associated with longer survival. After adjusting for patient factors and drop-out, survival was longer after PCV+RT (HR=0.66, 95% CI=0.49–0.9, P=0.0084; HR=0.74, 95% CI=0.54–1.01, P=0.0592) in models with MMSE and B-QOL. There were no differences in MMSE and B-QOL scores between arms (P=0.4752 and P=0.2767, respectively); higher scores predicted longer survival. Conclusions: MMSE and B-QOL scores held steady in both arms for survivors. For those who died, B-QOL scores declined slowly until the last year of life, then rapidly. Younger, fitter patients had better MMSE and B-QOL scores and longer survival. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Wang
- American College of Radiology, Philadelphia, PA; University of Calgary, Calgary, AB, Canada; Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic, Rochester, MN; Foundation for Cancer Research, Phoenix, AZ; McGill University, Montreal, QC, Canada; University of Toronto, Toronto, ON, Canada; University of Wisconsin, Madison, WI; Emory University Medical Center, Atlanta, GA
| | - G. Cairncross
- American College of Radiology, Philadelphia, PA; University of Calgary, Calgary, AB, Canada; Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic, Rochester, MN; Foundation for Cancer Research, Phoenix, AZ; McGill University, Montreal, QC, Canada; University of Toronto, Toronto, ON, Canada; University of Wisconsin, Madison, WI; Emory University Medical Center, Atlanta, GA
| | - E. Shaw
- American College of Radiology, Philadelphia, PA; University of Calgary, Calgary, AB, Canada; Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic, Rochester, MN; Foundation for Cancer Research, Phoenix, AZ; McGill University, Montreal, QC, Canada; University of Toronto, Toronto, ON, Canada; University of Wisconsin, Madison, WI; Emory University Medical Center, Atlanta, GA
| | - R. Jenkins
- American College of Radiology, Philadelphia, PA; University of Calgary, Calgary, AB, Canada; Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic, Rochester, MN; Foundation for Cancer Research, Phoenix, AZ; McGill University, Montreal, QC, Canada; University of Toronto, Toronto, ON, Canada; University of Wisconsin, Madison, WI; Emory University Medical Center, Atlanta, GA
| | - B. Scheithauer
- American College of Radiology, Philadelphia, PA; University of Calgary, Calgary, AB, Canada; Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic, Rochester, MN; Foundation for Cancer Research, Phoenix, AZ; McGill University, Montreal, QC, Canada; University of Toronto, Toronto, ON, Canada; University of Wisconsin, Madison, WI; Emory University Medical Center, Atlanta, GA
| | - D. Brachman
- American College of Radiology, Philadelphia, PA; University of Calgary, Calgary, AB, Canada; Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic, Rochester, MN; Foundation for Cancer Research, Phoenix, AZ; McGill University, Montreal, QC, Canada; University of Toronto, Toronto, ON, Canada; University of Wisconsin, Madison, WI; Emory University Medical Center, Atlanta, GA
| | - J. Buckner
- American College of Radiology, Philadelphia, PA; University of Calgary, Calgary, AB, Canada; Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic, Rochester, MN; Foundation for Cancer Research, Phoenix, AZ; McGill University, Montreal, QC, Canada; University of Toronto, Toronto, ON, Canada; University of Wisconsin, Madison, WI; Emory University Medical Center, Atlanta, GA
| | - L. Souhami
- American College of Radiology, Philadelphia, PA; University of Calgary, Calgary, AB, Canada; Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic, Rochester, MN; Foundation for Cancer Research, Phoenix, AZ; McGill University, Montreal, QC, Canada; University of Toronto, Toronto, ON, Canada; University of Wisconsin, Madison, WI; Emory University Medical Center, Atlanta, GA
| | - N. Laperriere
- American College of Radiology, Philadelphia, PA; University of Calgary, Calgary, AB, Canada; Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic, Rochester, MN; Foundation for Cancer Research, Phoenix, AZ; McGill University, Montreal, QC, Canada; University of Toronto, Toronto, ON, Canada; University of Wisconsin, Madison, WI; Emory University Medical Center, Atlanta, GA
| | - M. Mehta
- American College of Radiology, Philadelphia, PA; University of Calgary, Calgary, AB, Canada; Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic, Rochester, MN; Foundation for Cancer Research, Phoenix, AZ; McGill University, Montreal, QC, Canada; University of Toronto, Toronto, ON, Canada; University of Wisconsin, Madison, WI; Emory University Medical Center, Atlanta, GA
| | - W. Curran
- American College of Radiology, Philadelphia, PA; University of Calgary, Calgary, AB, Canada; Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic, Rochester, MN; Foundation for Cancer Research, Phoenix, AZ; McGill University, Montreal, QC, Canada; University of Toronto, Toronto, ON, Canada; University of Wisconsin, Madison, WI; Emory University Medical Center, Atlanta, GA
| |
Collapse
|
20
|
Shaw EG, Wang M, Coons S, Brachman D, Buckner JC, Stelzer K, Barger G, Brown PD, Gilbert MR, Mehta MP. Final report of Radiation Therapy Oncology Group (RTOG) protocol 9802: Radiation therapy (RT) versus RT + procarbazine, CCNU, and vincristine (PCV) chemotherapy for adult low-grade glioma (LGG). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.2006] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
21
|
Barasch A, Spijkervet F, Garden A, Kudrimoti MR, Brachman D, Brennan M, Tishler RB, Elting L, Keefe D, Sonis S. Efficacy of opioid analgesics and effect on functional status of pain caused by radiation-induced mucositis among patients with head and neck cancer. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.6019] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
22
|
Shapiro WR, Mehta MP, Langer C, Bezjak A, Timmerman R, Brachman D, Suh J, Smith JA, Phan S, Renschler MF. Motexafin gadolinium (MGd) combined with whole brain radiation therapy prolongs time to neurologic progression in non- small cell lung cancer (NSCLC) patients with brain metastases: Pooled analysis of two randomized phase III trials. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.2010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2010 Background: In 2 randomized trials, whole brain radiation therapy (RT) plus MGd prolonged time to neurologic progression (TNP) in NSCLC patients (pts) with brain metastases (BM). In this report, results of a pooled analysis from both trials are presented. Methods: In trial 9801, 401 pts with BM from solid tumors were randomized to RT (30 Gy) or RT+MGd, 5 mg/kg qd x 10 days. The subgroup of 251 pts with NSCLC is included in this analysis. In trial 0211, 554 pts with BM from NSCLC were randomized to the same treatments. In both trials, eligibility included a KPS = 70, no liver metastases, and = 1 site of extracranial metastasis. In both trials, a primary endpoint was time to neurologic progression determined by a blinded events review committee (ERC), incorporating data from neurologic exams, neurologic symptom collection, and neurocognitive tests. Results: 805 pts received RT (N=403) or RT+MGd (N=402). Most pts had multiple BM (80%), extracranial metastases (47%) and presented with neurologic deficits (84%). Treatment with MGd was well tolerated, with 93.3% of intended doses administered. Most common MGd-related grade 3+ adverse events were hypertension (4.6%), and fatigue (2.8%). TNP in the RT+MGd group was 15.4 mo, significantly longer than the 9.0 mo for the RT alone group, p=0.016, HR=0.74 (95% CI 0.57–0.95). The results of both studies are consistent, as shown in the table below. Similar results were observed in time to investigator-determined neurologic progression (p=0.015, HR=0.76) and time to neurocognitive progression (memory: HR=0.80, p=0.047, executive function: HR=0.74, p=0.028, all tests combined: HR=0.78, p=0.020). Conclusions: Motexafin gadolinium significantly prolonged time to neurologic progression and neurocognitive progression in NSCLC patients with brain metastases undergoing whole brain radiation therapy in a pooled analysis of 2 randomized phase III trials. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- W. R. Shapiro
- Barrow Neurological Institute, Phoenix, AZ; University of Wisconsin, Madison, WI; Fox Chase Cancer Center, Philadelphia, PA; Princess Margaret Hospital, Toronto, ON, Canada; University of Texas Southwestern Medical Center, Dallas, TX; St. Joseph’s Hospital, Phoenix, AZ; Cleveland Clinic, Cleveland, OH; Pharmacyclics, Sunnyvale, CA
| | - M. P. Mehta
- Barrow Neurological Institute, Phoenix, AZ; University of Wisconsin, Madison, WI; Fox Chase Cancer Center, Philadelphia, PA; Princess Margaret Hospital, Toronto, ON, Canada; University of Texas Southwestern Medical Center, Dallas, TX; St. Joseph’s Hospital, Phoenix, AZ; Cleveland Clinic, Cleveland, OH; Pharmacyclics, Sunnyvale, CA
| | - C. Langer
- Barrow Neurological Institute, Phoenix, AZ; University of Wisconsin, Madison, WI; Fox Chase Cancer Center, Philadelphia, PA; Princess Margaret Hospital, Toronto, ON, Canada; University of Texas Southwestern Medical Center, Dallas, TX; St. Joseph’s Hospital, Phoenix, AZ; Cleveland Clinic, Cleveland, OH; Pharmacyclics, Sunnyvale, CA
| | - A. Bezjak
- Barrow Neurological Institute, Phoenix, AZ; University of Wisconsin, Madison, WI; Fox Chase Cancer Center, Philadelphia, PA; Princess Margaret Hospital, Toronto, ON, Canada; University of Texas Southwestern Medical Center, Dallas, TX; St. Joseph’s Hospital, Phoenix, AZ; Cleveland Clinic, Cleveland, OH; Pharmacyclics, Sunnyvale, CA
| | - R. Timmerman
- Barrow Neurological Institute, Phoenix, AZ; University of Wisconsin, Madison, WI; Fox Chase Cancer Center, Philadelphia, PA; Princess Margaret Hospital, Toronto, ON, Canada; University of Texas Southwestern Medical Center, Dallas, TX; St. Joseph’s Hospital, Phoenix, AZ; Cleveland Clinic, Cleveland, OH; Pharmacyclics, Sunnyvale, CA
| | - D. Brachman
- Barrow Neurological Institute, Phoenix, AZ; University of Wisconsin, Madison, WI; Fox Chase Cancer Center, Philadelphia, PA; Princess Margaret Hospital, Toronto, ON, Canada; University of Texas Southwestern Medical Center, Dallas, TX; St. Joseph’s Hospital, Phoenix, AZ; Cleveland Clinic, Cleveland, OH; Pharmacyclics, Sunnyvale, CA
| | - J. Suh
- Barrow Neurological Institute, Phoenix, AZ; University of Wisconsin, Madison, WI; Fox Chase Cancer Center, Philadelphia, PA; Princess Margaret Hospital, Toronto, ON, Canada; University of Texas Southwestern Medical Center, Dallas, TX; St. Joseph’s Hospital, Phoenix, AZ; Cleveland Clinic, Cleveland, OH; Pharmacyclics, Sunnyvale, CA
| | - J. A. Smith
- Barrow Neurological Institute, Phoenix, AZ; University of Wisconsin, Madison, WI; Fox Chase Cancer Center, Philadelphia, PA; Princess Margaret Hospital, Toronto, ON, Canada; University of Texas Southwestern Medical Center, Dallas, TX; St. Joseph’s Hospital, Phoenix, AZ; Cleveland Clinic, Cleveland, OH; Pharmacyclics, Sunnyvale, CA
| | - S. Phan
- Barrow Neurological Institute, Phoenix, AZ; University of Wisconsin, Madison, WI; Fox Chase Cancer Center, Philadelphia, PA; Princess Margaret Hospital, Toronto, ON, Canada; University of Texas Southwestern Medical Center, Dallas, TX; St. Joseph’s Hospital, Phoenix, AZ; Cleveland Clinic, Cleveland, OH; Pharmacyclics, Sunnyvale, CA
| | - M. F. Renschler
- Barrow Neurological Institute, Phoenix, AZ; University of Wisconsin, Madison, WI; Fox Chase Cancer Center, Philadelphia, PA; Princess Margaret Hospital, Toronto, ON, Canada; University of Texas Southwestern Medical Center, Dallas, TX; St. Joseph’s Hospital, Phoenix, AZ; Cleveland Clinic, Cleveland, OH; Pharmacyclics, Sunnyvale, CA
| |
Collapse
|
23
|
Elting LS, Calais G, Selva N, Brachman D, Kudrimoti M, Spijkervet F, Vera-Llonch M, Oster G, Keefe D, Sonis ST. Patient-reported burden of mucosal injury (MUI): Comparison of clinician-rated MUI and patient-reported outcomes. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.9117] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9117 Background: Patient (pt) reported outcome (PROs) tools identify MUI and its impact on functional and subjective outcomes. Among outpts, PRO tools are attractive because opportunities for direct assessment are limited, but agreement between PRO tools and objective MUI measures has not been uniform. We prospectively compared an objective MUI score and 3 previously validated PRO tools. Method: The Triad Burden of Illness study is an international, 41-center, prospective study of the risk and outcomes of radiation and chemotherapy-induced MUI. At baseline and during chemoradiation therapy (CRT), pts with larynx (L), hypopharynx (H), or non-small cell lung cancers (NSCLC) completed a daily MUI symptom tool (OMDQ) and 2 weekly PRO tools (FACT-E quality of life, FACIT- Fatigue). Clinicians examined pts twice weekly and scored MUI (WHO scale). In this interim analysis, we used random effects linear regression to compare clinician and pt ratings and t-tests to compare PRO scores in pts with and without severe MUI. Result: To date, 29 pts have completed =2 paired assessments; 23 (79%) had L or H cancers. Ulcerative MUI (WHO = 2) was more common among L/H than NSCLC pts (39% vs 17%). Pt-rated MUI predicted clinician-rated MUI (p = 0.001). FACT-E and FACIT-F scores were significantly lower (worse) among pts with clinician-rated ulcerative MUI than pts without and among pts with pt-rated severe MUI symptoms (OMDQ= 2) than pts without. Differences were largest in the subscales for physical and functional wellbeing and esophageal symptom special concerns. Conclusion: PRO tools estimate the burden of CRT-induced MUI in outpts with L/H or NCSL cancers. MUI appears to be associated with significantly poorer quality of life, functional status, and symptom scores. 1- 9 p <0.01; 10p = 0.06. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- L. S. Elting
- UT MD Anderson Cancer Center, Houston, TX; Centre Regional, Bretonneau, France; Royal Adelaide Hospital Cancer Centre, North Terrace, Adelaide SA, Australia; St. Joseph's Hospital, Phoenix, AZ; University of Kentucky, Lexington, KY; University Medical Center Groningen, Groningen, Netherlands Antilles; Policy Analysis, Inc (PAI), Brookline, MA; University of Adelaide, Adelaide, South Australia, Australia; Brigham and Women's Hospital, Boston, MA
| | - G. Calais
- UT MD Anderson Cancer Center, Houston, TX; Centre Regional, Bretonneau, France; Royal Adelaide Hospital Cancer Centre, North Terrace, Adelaide SA, Australia; St. Joseph's Hospital, Phoenix, AZ; University of Kentucky, Lexington, KY; University Medical Center Groningen, Groningen, Netherlands Antilles; Policy Analysis, Inc (PAI), Brookline, MA; University of Adelaide, Adelaide, South Australia, Australia; Brigham and Women's Hospital, Boston, MA
| | - N. Selva
- UT MD Anderson Cancer Center, Houston, TX; Centre Regional, Bretonneau, France; Royal Adelaide Hospital Cancer Centre, North Terrace, Adelaide SA, Australia; St. Joseph's Hospital, Phoenix, AZ; University of Kentucky, Lexington, KY; University Medical Center Groningen, Groningen, Netherlands Antilles; Policy Analysis, Inc (PAI), Brookline, MA; University of Adelaide, Adelaide, South Australia, Australia; Brigham and Women's Hospital, Boston, MA
| | - D. Brachman
- UT MD Anderson Cancer Center, Houston, TX; Centre Regional, Bretonneau, France; Royal Adelaide Hospital Cancer Centre, North Terrace, Adelaide SA, Australia; St. Joseph's Hospital, Phoenix, AZ; University of Kentucky, Lexington, KY; University Medical Center Groningen, Groningen, Netherlands Antilles; Policy Analysis, Inc (PAI), Brookline, MA; University of Adelaide, Adelaide, South Australia, Australia; Brigham and Women's Hospital, Boston, MA
| | - M. Kudrimoti
- UT MD Anderson Cancer Center, Houston, TX; Centre Regional, Bretonneau, France; Royal Adelaide Hospital Cancer Centre, North Terrace, Adelaide SA, Australia; St. Joseph's Hospital, Phoenix, AZ; University of Kentucky, Lexington, KY; University Medical Center Groningen, Groningen, Netherlands Antilles; Policy Analysis, Inc (PAI), Brookline, MA; University of Adelaide, Adelaide, South Australia, Australia; Brigham and Women's Hospital, Boston, MA
| | - F. Spijkervet
- UT MD Anderson Cancer Center, Houston, TX; Centre Regional, Bretonneau, France; Royal Adelaide Hospital Cancer Centre, North Terrace, Adelaide SA, Australia; St. Joseph's Hospital, Phoenix, AZ; University of Kentucky, Lexington, KY; University Medical Center Groningen, Groningen, Netherlands Antilles; Policy Analysis, Inc (PAI), Brookline, MA; University of Adelaide, Adelaide, South Australia, Australia; Brigham and Women's Hospital, Boston, MA
| | - M. Vera-Llonch
- UT MD Anderson Cancer Center, Houston, TX; Centre Regional, Bretonneau, France; Royal Adelaide Hospital Cancer Centre, North Terrace, Adelaide SA, Australia; St. Joseph's Hospital, Phoenix, AZ; University of Kentucky, Lexington, KY; University Medical Center Groningen, Groningen, Netherlands Antilles; Policy Analysis, Inc (PAI), Brookline, MA; University of Adelaide, Adelaide, South Australia, Australia; Brigham and Women's Hospital, Boston, MA
| | - G. Oster
- UT MD Anderson Cancer Center, Houston, TX; Centre Regional, Bretonneau, France; Royal Adelaide Hospital Cancer Centre, North Terrace, Adelaide SA, Australia; St. Joseph's Hospital, Phoenix, AZ; University of Kentucky, Lexington, KY; University Medical Center Groningen, Groningen, Netherlands Antilles; Policy Analysis, Inc (PAI), Brookline, MA; University of Adelaide, Adelaide, South Australia, Australia; Brigham and Women's Hospital, Boston, MA
| | - D. Keefe
- UT MD Anderson Cancer Center, Houston, TX; Centre Regional, Bretonneau, France; Royal Adelaide Hospital Cancer Centre, North Terrace, Adelaide SA, Australia; St. Joseph's Hospital, Phoenix, AZ; University of Kentucky, Lexington, KY; University Medical Center Groningen, Groningen, Netherlands Antilles; Policy Analysis, Inc (PAI), Brookline, MA; University of Adelaide, Adelaide, South Australia, Australia; Brigham and Women's Hospital, Boston, MA
| | - S. T. Sonis
- UT MD Anderson Cancer Center, Houston, TX; Centre Regional, Bretonneau, France; Royal Adelaide Hospital Cancer Centre, North Terrace, Adelaide SA, Australia; St. Joseph's Hospital, Phoenix, AZ; University of Kentucky, Lexington, KY; University Medical Center Groningen, Groningen, Netherlands Antilles; Policy Analysis, Inc (PAI), Brookline, MA; University of Adelaide, Adelaide, South Australia, Australia; Brigham and Women's Hospital, Boston, MA
| | | |
Collapse
|
24
|
Chakravarti A, Berkey B, Robins H, Guha A, Curran W, Brachman D, Shultz C, Mehta M. 149. Int J Radiat Oncol Biol Phys 2006. [DOI: 10.1016/j.ijrobp.2006.07.180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
25
|
Chakravarti A, Berkey B, Robins HI, Guha A, Curran WJ, Brachman D, Shultz C, Mehta M. An update of phase II results from RTOG 0211: A phase I/II study of gefitinib with radiotherapy in newly diagnosed glioblastoma. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.1527] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1527 Background: The epidermal growth factor receptor (EGFR) pathway is commonly deregulated in GBMs and its activity has been associated with treatment resistance in preclinical models. Accordingly, the Radiation Therapy Oncology Group (RTOG) recently conducted a Phase I/II study of Gefitinib, an EGFR tyrosine kinase inhibitor, in combination with radiotherapy for newly-diagnosed glioblastoma (GBM) patients. Methods: 178 GBM patients were entered on RTOG 0211 (Phase I: 31 patients and Phase II: 147 patients). The maximum tolerated dose (MTD) of Gefitinib was determined to be 500mg in non-EIACD patients, and the Phase II component of RTOG 0211 was continued at this dose level during radiation and as maintenance for 18 months afterward or until disease progression. Results: 119/147 patients completed treatment per protocol and/or with acceptable deviation. The median survival time for all patients in the study was 11.0 months. Progression-free survival was 5.1 months for all patients. When considering only patients who were treated per protocol, the median survival of RTOG 0211 patients was 11.5 months, compared to 11.0 months for historical controls treated in previous RTOG studies (p=0.14). RPA Class IV patients appeared to derive the greatest benefit from Gefitinib when combined with radiotherapy compared to historical controls, although not reaching statistical significance. Molecular and genetic profiling efforts are underway to determine which GBM patients derive greatest benefit from Gefitinib in the upfront setting, which will be reported at the time of the annual meeting. These include markers such as EGFRvIII and PTEN, which have been recently reported to be associated with response to anti-EGFR agents in the recurrent setting, and members of key signal transduction pathways regulated by EGFR. Conclusions: The observed survival advantage of newly-diagnosed GBM patients treated with Gefitinib in combination with radiotherapy compared to historical controls treated on previous RTOG studies does not reach statistical significance. Molecular and genetic profiling efforts are underway to identify subsets of GBM patients who might derive the greatest benefit from Gefitinib in the upfront setting. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Chakravarti
- Massachusetts General Hospital, Boston, MA; American College of Radiology, Philadelphia, PA; University of Wisconsin, Madison, WI; University of Toronto, Toronto, ON, Canada; Thomas Jefferson Medical College, Philadelphia, PA; Foundation for Cancer Research and Education, Phoenix, AZ; Medical College of Wisconsin, Milwaukee, WI
| | - B. Berkey
- Massachusetts General Hospital, Boston, MA; American College of Radiology, Philadelphia, PA; University of Wisconsin, Madison, WI; University of Toronto, Toronto, ON, Canada; Thomas Jefferson Medical College, Philadelphia, PA; Foundation for Cancer Research and Education, Phoenix, AZ; Medical College of Wisconsin, Milwaukee, WI
| | - H. I. Robins
- Massachusetts General Hospital, Boston, MA; American College of Radiology, Philadelphia, PA; University of Wisconsin, Madison, WI; University of Toronto, Toronto, ON, Canada; Thomas Jefferson Medical College, Philadelphia, PA; Foundation for Cancer Research and Education, Phoenix, AZ; Medical College of Wisconsin, Milwaukee, WI
| | - A. Guha
- Massachusetts General Hospital, Boston, MA; American College of Radiology, Philadelphia, PA; University of Wisconsin, Madison, WI; University of Toronto, Toronto, ON, Canada; Thomas Jefferson Medical College, Philadelphia, PA; Foundation for Cancer Research and Education, Phoenix, AZ; Medical College of Wisconsin, Milwaukee, WI
| | - W. J. Curran
- Massachusetts General Hospital, Boston, MA; American College of Radiology, Philadelphia, PA; University of Wisconsin, Madison, WI; University of Toronto, Toronto, ON, Canada; Thomas Jefferson Medical College, Philadelphia, PA; Foundation for Cancer Research and Education, Phoenix, AZ; Medical College of Wisconsin, Milwaukee, WI
| | - D. Brachman
- Massachusetts General Hospital, Boston, MA; American College of Radiology, Philadelphia, PA; University of Wisconsin, Madison, WI; University of Toronto, Toronto, ON, Canada; Thomas Jefferson Medical College, Philadelphia, PA; Foundation for Cancer Research and Education, Phoenix, AZ; Medical College of Wisconsin, Milwaukee, WI
| | - C. Shultz
- Massachusetts General Hospital, Boston, MA; American College of Radiology, Philadelphia, PA; University of Wisconsin, Madison, WI; University of Toronto, Toronto, ON, Canada; Thomas Jefferson Medical College, Philadelphia, PA; Foundation for Cancer Research and Education, Phoenix, AZ; Medical College of Wisconsin, Milwaukee, WI
| | - M. Mehta
- Massachusetts General Hospital, Boston, MA; American College of Radiology, Philadelphia, PA; University of Wisconsin, Madison, WI; University of Toronto, Toronto, ON, Canada; Thomas Jefferson Medical College, Philadelphia, PA; Foundation for Cancer Research and Education, Phoenix, AZ; Medical College of Wisconsin, Milwaukee, WI
| |
Collapse
|
26
|
Shaw EG, Berkey B, Coons SW, Brachman D, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta M. Initial report of Radiation Therapy Oncology Group (RTOG) 9802: Prospective studies in adult low-grade glioma (LGG). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.1500] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1500 Background: Treatment of adult LGG is controversial. Favorable patients (pts) (age <40 years [yrs] who undergo gross total resection [GTR]) are typically observed. Unfavorable pts (age ≥40 who have subtotal resection [STR] or biopsy [B]) are usually given initial radiation therapy (RT), reserving chemotherapy (historically procarbazine, CCNU and vincristine [PCV]) for recurrence. In 1998, the RTOG, in conjunction with SWOG, NCCTG, and ECOG initiated prospective studies of adult LGG, the results of which are reported herein. Methods: Favorable pts were observed postoperatively in a single arm Phase II study (Arm 1). Unfavorable pts were stratified by age, histology, KPS, and presence/absence of contrast enhancement on preoperative magnetic resonance imaging and randomized to either RT alone (54Gy in 30 fractions to a local treatment field) (Arm 2) or RT followed by 6 cycles of standard dose PCV (Arm 3). Reported results include overall survival (OS) rate, median overall survival time (MOST), progression-free survival (PFS) rate, and median progression-free survival time (MPFST). Survival data are compared using Wilcoxon p-values. Results: A total of 362 eligible/analyzable pts were accrued between 1998 and 2002. Median follow-up time is 4 years. For the 111 favorable pts observed on Arm 1, OS at 2- and 5-yrs is 99% and 94%. PFS at 2- and 5-yrs is 82% and 50%. For the 251 unfavorable pts on Arms 2 (RT alone) and 3 (RT+PCV), there was no difference in OS or PFS. OS at 2- and 5-yrs was 87% and 61% with RT alone versus (vs) 86% and 70% with RT+PCV (p=0.72). MOST was not reached in RT alone pts and was 6.0 yrs in RT+PCV pts. PFS at 2- and 5-yrs was 73% and 39% with RT alone vs 72% and 61% with RT+PCV (p=0.38). MPFST was 4.0 yrs with RT alone vs 6.0 yrs with RT+PCV. Acute grade 3–4 toxicity occurred in 9% of pts who received RT alone, 67% who received RT+PCV (mostly hematologic). There were no treatment deaths on either arm. Conclusions: 5-yr PFS was poor in all three arms ranging from 39% to 61%. Only half of favorable pts were disease-free at 5 yrs. In unfavorable pts, there was no OS advantage with the addition of PCV to RT. Both PFS and MPFST were better with the addition of PCV, but not significantly. Analysis of outcome by 1p19q status is pending. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- E. G. Shaw
- Wake Forest University School of Medicine, Winston Salem, NC; Radiation Therapy Oncology Group, Philadelphia, PA; Barrow Neurological Institute, Phoenix, AZ; Mayo Clinic, Rochester, MN; University of Washington, Seattle, WA; Wayne State University School of Medicine, Detroit, MI; M. D. Anderson Cancer Center, Houston, TX; University of Wisconsin Medical School, Madison, WI
| | - B. Berkey
- Wake Forest University School of Medicine, Winston Salem, NC; Radiation Therapy Oncology Group, Philadelphia, PA; Barrow Neurological Institute, Phoenix, AZ; Mayo Clinic, Rochester, MN; University of Washington, Seattle, WA; Wayne State University School of Medicine, Detroit, MI; M. D. Anderson Cancer Center, Houston, TX; University of Wisconsin Medical School, Madison, WI
| | - S. W. Coons
- Wake Forest University School of Medicine, Winston Salem, NC; Radiation Therapy Oncology Group, Philadelphia, PA; Barrow Neurological Institute, Phoenix, AZ; Mayo Clinic, Rochester, MN; University of Washington, Seattle, WA; Wayne State University School of Medicine, Detroit, MI; M. D. Anderson Cancer Center, Houston, TX; University of Wisconsin Medical School, Madison, WI
| | - D. Brachman
- Wake Forest University School of Medicine, Winston Salem, NC; Radiation Therapy Oncology Group, Philadelphia, PA; Barrow Neurological Institute, Phoenix, AZ; Mayo Clinic, Rochester, MN; University of Washington, Seattle, WA; Wayne State University School of Medicine, Detroit, MI; M. D. Anderson Cancer Center, Houston, TX; University of Wisconsin Medical School, Madison, WI
| | - J. C. Buckner
- Wake Forest University School of Medicine, Winston Salem, NC; Radiation Therapy Oncology Group, Philadelphia, PA; Barrow Neurological Institute, Phoenix, AZ; Mayo Clinic, Rochester, MN; University of Washington, Seattle, WA; Wayne State University School of Medicine, Detroit, MI; M. D. Anderson Cancer Center, Houston, TX; University of Wisconsin Medical School, Madison, WI
| | - K. J. Stelzer
- Wake Forest University School of Medicine, Winston Salem, NC; Radiation Therapy Oncology Group, Philadelphia, PA; Barrow Neurological Institute, Phoenix, AZ; Mayo Clinic, Rochester, MN; University of Washington, Seattle, WA; Wayne State University School of Medicine, Detroit, MI; M. D. Anderson Cancer Center, Houston, TX; University of Wisconsin Medical School, Madison, WI
| | - G. R. Barger
- Wake Forest University School of Medicine, Winston Salem, NC; Radiation Therapy Oncology Group, Philadelphia, PA; Barrow Neurological Institute, Phoenix, AZ; Mayo Clinic, Rochester, MN; University of Washington, Seattle, WA; Wayne State University School of Medicine, Detroit, MI; M. D. Anderson Cancer Center, Houston, TX; University of Wisconsin Medical School, Madison, WI
| | - P. D. Brown
- Wake Forest University School of Medicine, Winston Salem, NC; Radiation Therapy Oncology Group, Philadelphia, PA; Barrow Neurological Institute, Phoenix, AZ; Mayo Clinic, Rochester, MN; University of Washington, Seattle, WA; Wayne State University School of Medicine, Detroit, MI; M. D. Anderson Cancer Center, Houston, TX; University of Wisconsin Medical School, Madison, WI
| | - M. R. Gilbert
- Wake Forest University School of Medicine, Winston Salem, NC; Radiation Therapy Oncology Group, Philadelphia, PA; Barrow Neurological Institute, Phoenix, AZ; Mayo Clinic, Rochester, MN; University of Washington, Seattle, WA; Wayne State University School of Medicine, Detroit, MI; M. D. Anderson Cancer Center, Houston, TX; University of Wisconsin Medical School, Madison, WI
| | - M. Mehta
- Wake Forest University School of Medicine, Winston Salem, NC; Radiation Therapy Oncology Group, Philadelphia, PA; Barrow Neurological Institute, Phoenix, AZ; Mayo Clinic, Rochester, MN; University of Washington, Seattle, WA; Wayne State University School of Medicine, Detroit, MI; M. D. Anderson Cancer Center, Houston, TX; University of Wisconsin Medical School, Madison, WI
| |
Collapse
|
27
|
Cairncross G, Seiferheld W, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Curran W. An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: Initial report of RTOG 94–02. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.1500] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- G. Cairncross
- University of Calgary, Calgary, AB, Canada; American College of Radiology, Philadelphia, PA; Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic, Rochester, MN; Foundation for Cancer Research, Phoenix, AZ; University of Texas Southwestern Medical Center, Dallas, TX; McGill University, Montreal, PQ, Canada; Thomas Jefferson University Hospital, Philadelphia, PA
| | - W. Seiferheld
- University of Calgary, Calgary, AB, Canada; American College of Radiology, Philadelphia, PA; Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic, Rochester, MN; Foundation for Cancer Research, Phoenix, AZ; University of Texas Southwestern Medical Center, Dallas, TX; McGill University, Montreal, PQ, Canada; Thomas Jefferson University Hospital, Philadelphia, PA
| | - E. Shaw
- University of Calgary, Calgary, AB, Canada; American College of Radiology, Philadelphia, PA; Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic, Rochester, MN; Foundation for Cancer Research, Phoenix, AZ; University of Texas Southwestern Medical Center, Dallas, TX; McGill University, Montreal, PQ, Canada; Thomas Jefferson University Hospital, Philadelphia, PA
| | - R. Jenkins
- University of Calgary, Calgary, AB, Canada; American College of Radiology, Philadelphia, PA; Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic, Rochester, MN; Foundation for Cancer Research, Phoenix, AZ; University of Texas Southwestern Medical Center, Dallas, TX; McGill University, Montreal, PQ, Canada; Thomas Jefferson University Hospital, Philadelphia, PA
| | - B. Scheithauer
- University of Calgary, Calgary, AB, Canada; American College of Radiology, Philadelphia, PA; Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic, Rochester, MN; Foundation for Cancer Research, Phoenix, AZ; University of Texas Southwestern Medical Center, Dallas, TX; McGill University, Montreal, PQ, Canada; Thomas Jefferson University Hospital, Philadelphia, PA
| | - D. Brachman
- University of Calgary, Calgary, AB, Canada; American College of Radiology, Philadelphia, PA; Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic, Rochester, MN; Foundation for Cancer Research, Phoenix, AZ; University of Texas Southwestern Medical Center, Dallas, TX; McGill University, Montreal, PQ, Canada; Thomas Jefferson University Hospital, Philadelphia, PA
| | - J. Buckner
- University of Calgary, Calgary, AB, Canada; American College of Radiology, Philadelphia, PA; Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic, Rochester, MN; Foundation for Cancer Research, Phoenix, AZ; University of Texas Southwestern Medical Center, Dallas, TX; McGill University, Montreal, PQ, Canada; Thomas Jefferson University Hospital, Philadelphia, PA
| | - K. Fink
- University of Calgary, Calgary, AB, Canada; American College of Radiology, Philadelphia, PA; Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic, Rochester, MN; Foundation for Cancer Research, Phoenix, AZ; University of Texas Southwestern Medical Center, Dallas, TX; McGill University, Montreal, PQ, Canada; Thomas Jefferson University Hospital, Philadelphia, PA
| | - L. Souhami
- University of Calgary, Calgary, AB, Canada; American College of Radiology, Philadelphia, PA; Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic, Rochester, MN; Foundation for Cancer Research, Phoenix, AZ; University of Texas Southwestern Medical Center, Dallas, TX; McGill University, Montreal, PQ, Canada; Thomas Jefferson University Hospital, Philadelphia, PA
| | - W. Curran
- University of Calgary, Calgary, AB, Canada; American College of Radiology, Philadelphia, PA; Wake Forest University School of Medicine, Winston-Salem, NC; Mayo Clinic, Rochester, MN; Foundation for Cancer Research, Phoenix, AZ; University of Texas Southwestern Medical Center, Dallas, TX; McGill University, Montreal, PQ, Canada; Thomas Jefferson University Hospital, Philadelphia, PA
| |
Collapse
|
28
|
Chakravarti A, Seiferheld W, Robins HI, Guha A, Brachman D, Curran W, Choucair A, Mehta M. An update of phase I data from RTOG 0211: A phase I/II clinical study of gefitinib+ radiation for newly-diagnosed glioblastoma (GBM) patients. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.1571] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. Chakravarti
- Massachusetts General Hospital, Boston, MA; American College of Radiology, Philadelphia, PA; University of Wisconsin, Madison, WI; University of Toronto, Toronto, ON; Foundation for Cancer Research, Phoenix, AZ; Thomas Jefferson University, Philadelphia, PA; LDS Hospital, Salt Lake City, UT
| | - W. Seiferheld
- Massachusetts General Hospital, Boston, MA; American College of Radiology, Philadelphia, PA; University of Wisconsin, Madison, WI; University of Toronto, Toronto, ON; Foundation for Cancer Research, Phoenix, AZ; Thomas Jefferson University, Philadelphia, PA; LDS Hospital, Salt Lake City, UT
| | - H. I. Robins
- Massachusetts General Hospital, Boston, MA; American College of Radiology, Philadelphia, PA; University of Wisconsin, Madison, WI; University of Toronto, Toronto, ON; Foundation for Cancer Research, Phoenix, AZ; Thomas Jefferson University, Philadelphia, PA; LDS Hospital, Salt Lake City, UT
| | - A. Guha
- Massachusetts General Hospital, Boston, MA; American College of Radiology, Philadelphia, PA; University of Wisconsin, Madison, WI; University of Toronto, Toronto, ON; Foundation for Cancer Research, Phoenix, AZ; Thomas Jefferson University, Philadelphia, PA; LDS Hospital, Salt Lake City, UT
| | - D. Brachman
- Massachusetts General Hospital, Boston, MA; American College of Radiology, Philadelphia, PA; University of Wisconsin, Madison, WI; University of Toronto, Toronto, ON; Foundation for Cancer Research, Phoenix, AZ; Thomas Jefferson University, Philadelphia, PA; LDS Hospital, Salt Lake City, UT
| | - W. Curran
- Massachusetts General Hospital, Boston, MA; American College of Radiology, Philadelphia, PA; University of Wisconsin, Madison, WI; University of Toronto, Toronto, ON; Foundation for Cancer Research, Phoenix, AZ; Thomas Jefferson University, Philadelphia, PA; LDS Hospital, Salt Lake City, UT
| | - A. Choucair
- Massachusetts General Hospital, Boston, MA; American College of Radiology, Philadelphia, PA; University of Wisconsin, Madison, WI; University of Toronto, Toronto, ON; Foundation for Cancer Research, Phoenix, AZ; Thomas Jefferson University, Philadelphia, PA; LDS Hospital, Salt Lake City, UT
| | - M. Mehta
- Massachusetts General Hospital, Boston, MA; American College of Radiology, Philadelphia, PA; University of Wisconsin, Madison, WI; University of Toronto, Toronto, ON; Foundation for Cancer Research, Phoenix, AZ; Thomas Jefferson University, Philadelphia, PA; LDS Hospital, Salt Lake City, UT
| |
Collapse
|
29
|
Robins HI, Won M, Schultz C, Choucair A, Brachman D, Demas W, Mehta M. A phase II trial of conventional radiation therapy (XRT) plus high dose tamoxifen (TAM) for the treatment of supratentorial glioblastoma multiforme (GBM): RTOG protocol BR-0021. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.1529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- H. I. Robins
- UWCCC, Madison, WI; RTOG, Philadelphia, PA; Medical College of Wisconsin, Milwaukee, WI; LDS Hospital, Salt Lake City, UT; Foundation for Cancer Research and Education, Phoenix, AZ; Summa Health Systems, Akron, OH
| | - M. Won
- UWCCC, Madison, WI; RTOG, Philadelphia, PA; Medical College of Wisconsin, Milwaukee, WI; LDS Hospital, Salt Lake City, UT; Foundation for Cancer Research and Education, Phoenix, AZ; Summa Health Systems, Akron, OH
| | - C. Schultz
- UWCCC, Madison, WI; RTOG, Philadelphia, PA; Medical College of Wisconsin, Milwaukee, WI; LDS Hospital, Salt Lake City, UT; Foundation for Cancer Research and Education, Phoenix, AZ; Summa Health Systems, Akron, OH
| | - A. Choucair
- UWCCC, Madison, WI; RTOG, Philadelphia, PA; Medical College of Wisconsin, Milwaukee, WI; LDS Hospital, Salt Lake City, UT; Foundation for Cancer Research and Education, Phoenix, AZ; Summa Health Systems, Akron, OH
| | - D. Brachman
- UWCCC, Madison, WI; RTOG, Philadelphia, PA; Medical College of Wisconsin, Milwaukee, WI; LDS Hospital, Salt Lake City, UT; Foundation for Cancer Research and Education, Phoenix, AZ; Summa Health Systems, Akron, OH
| | - W. Demas
- UWCCC, Madison, WI; RTOG, Philadelphia, PA; Medical College of Wisconsin, Milwaukee, WI; LDS Hospital, Salt Lake City, UT; Foundation for Cancer Research and Education, Phoenix, AZ; Summa Health Systems, Akron, OH
| | - M. Mehta
- UWCCC, Madison, WI; RTOG, Philadelphia, PA; Medical College of Wisconsin, Milwaukee, WI; LDS Hospital, Salt Lake City, UT; Foundation for Cancer Research and Education, Phoenix, AZ; Summa Health Systems, Akron, OH
| |
Collapse
|
30
|
Rogers L, Pueschel J, Spetzler R, Shapiro W, Thomas T, Brachman D, Speiser B. Is gross total resection sufficient treatment for posterior fossa ependymomas. Int J Radiat Oncol Biol Phys 2002. [DOI: 10.1016/s0360-3016(02)03410-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
31
|
Souhami L, Scott C, Brachman D, Podgorsak E, Werner-Wasik M, Lustig R, Schultz C, Sause W, Okunieff P, Buckner J, Zamorano L, Mehta M, Curran W. Randomized prospective comparison of stereotactic radiosurgery (SRS) followed by conventional radiotherapy (RT) with BCNU to RT with BCNU alone for selected patients with supratentorial glioblastoma multiforme (GBM): report of RTOG 93-05 protocol. Int J Radiat Oncol Biol Phys 2002. [DOI: 10.1016/s0360-3016(02)03219-4] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
32
|
Jani AB, Vaida F, Hanks G, Asbell S, Sartor O, Moul JW, Roach M, Brachman D, Kalokhe U, Muller-Runkel R, Ray P, Ignacio L, Awan A, Weichselbaum RR, Vijayakumar S. Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era. Int J Cancer 2001; 96:363-71. [PMID: 11745507 DOI: 10.1002/ijc.1035] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
The purpose of this investigation was to examine changes in pretreatment prostate-specific antigen (PSA), stage, and grade over the past decade as a function of race and geographic region. A multiinstitutional database representing 6,790 patients (1,417 African-American, 5,373 white) diagnosed with nonmetastatic prostate cancer between 1988 and 1997 was constructed. PSA, stage, and grade data were tabulated by calendar year and region, and time trend analyses based on race and region were performed. There was an overall decline of PSA of 0.8%/year, which was significant (P = 0.0001), with a faster rate of decline in African-Americans (1.9%/year) than for whites (0.6%/year). The odds ratio (OR) for a stage shift was 1.09, which was significant (P < 0.0001), and this shift was greater in whites. The OR for an overall grade shift was 1.15, which was significant (P < 0.0001). Although grade and PSA trends were similar for the different regions, there were significant regional differences in stage trends. The implications are that the face of prostate cancer has changed over the past decade; i.e., the distributions of stage, grade, and PSA (the most important prognosticators) have changed. In addition, the countenances of that face are different for whites and African-Americans. For African-Americans, this is good news: the stage, grade, and PSA distributions are more favorable now than before. For whites, the trends are more complex and more dependent on region. These findings should be used for future clinical and health-policy decisions in the screening and treatment of prostate cancer.
Collapse
Affiliation(s)
- A B Jani
- Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Chen L, Haraf D, Brachman D, Vokes E, Schilsky R. Concomitant 5-FU, hydroxyurea and cisplatin with external beam radiation therapy for locally advanced pancreatic cancer. Oncol Rep 1997; 4:877-81. [PMID: 21590158 DOI: 10.3892/or.4.5.877] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The aim of the study was to determine the efficacy and toxicity of alternate week concurrent 5-fluorouracil, hydroxyurea, and cisplatin with radiotherapy for locally advanced pancreatic adenocarcinoma. Patients received 5-fluorouracil, hydroxyurea and cisplatin with radiotherapy on an alternate week basis. Chemoradiotherapy was given day 1-5, and no therapy given day 6-14 for each 14 day cycle. Chemotherapy doses were as follows: hydroxyurea 1 mg every 12 h starting day 0, 5-fluorouracil 800 mg/m(2)/day for 5 days starting day 1, and cisplatin 20 mg/m(2) daily for 5 days every other cycle. A radiation dose of 6000 cGy was prescribed. Acute toxicities were monitored and therapy modified for hematologic toxicity. Nine patients enrolled, however eight were evaluable; one patient expired prior to therapy. The median radiation dose delivered was 5540 cGy. Sixty-three percent required a chemotherapy dose reduction. Fifty percent achieved local control by radiographic imaging after completion of therapy. Median survival was 12 months. Acute toxicity included: 38% grade 2-3 nausea, 37% grade 2-3 vomiting, 63% grade 2-3 mucositis, 63% grade 2-3 neutropenia, and 88% grade 3-4 thrombocytopenia. Other sequelae included hand-foot syndrome, deep venous thrombosis, hearing loss, seizures, and anorexia. Patients achieved the same median survival as compared to other reported studies of radiation therapy with single agent 5-fluorouracil. We do not recommend this protocol due to the significant toxicity. Future studies to incorporate conformal radiation therapy with more active, less toxic chemotherapeutic agents should be investigated.
Collapse
Affiliation(s)
- L Chen
- UNIV CHICAGO,HEMATOL ONCOL SECT,CHICAGO,IL 60637. UNIV CHICAGO,CANC RES CTR,CHICAGO,IL 60637
| | | | | | | | | |
Collapse
|
34
|
Haraf DJ, Nodzenski E, Brachman D, Mick R, Montag A, Graves D, Vokes EE, Weichselbaum RR. Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival. Clin Cancer Res 1996; 2:755-62. [PMID: 9816227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
Recent studies have shown that p53 mutations are frequently found in cancer of the head and neck, whereas others have indicated that human papilloma virus (HPV) infection may be involved. Thus far, no studies have examined both p53 and HPV in the same patient population and correlated the results with clinical characteristics and outcome. The purpose of this study was to examine any interrelationship between p53 and HPV in patients with squamous cell carcinoma (SCC) of the head and neck. We also planned to correlate the experimental findings with clinical characteristics, known risk factors, and treatment outcome to determine whether any prognostic factors could be detected. Archival material from 66 patients with SCC of the head and neck were selected for study based on the availability of tissue from the primary tumors prior to treatment. A data base was constructed containing all clinical parameters at the time of diagnosis and risk factors. Genomic DNA was isolated and amplified using PCR, followed by SSCP analysis and direct genomic sequencing of all variants to detect p53 mutations. Two independent methods were used for HPV detection: (a) PCR amplification using primers homologous to the E6 region of HPV 16, 18, and 33, followed by RFLP analysis; and (b) PCR amplification with HPV L1 consensus primers, followed by triple restriction enzyme digestion. The results were entered into the data base for statistical analysis. Twenty-four percent of patients were found to have p53 mutations, and 18% were positive for HPV infection. Only one patient was positive for both. Tonsilar cancer was strongly correlated with HPV (P = 0.0001) and inversely correlated with p53 (P = 0.03). The only clinical parameter associated with p53 mutation was a trend toward a heavier smoking history. A subset analysis of the patients with tonsilar cancer revealed inverse correlations with smoking (P = 0. 015) and alcohol use (P = 0.05). Also, white patients with SCC of the tonsil were more likely to be HPV positive (P = 0.015). No significant relationships with outcome were detected with either p53 or HPV in the entire population. A subset analysis of patients with stage IV disease revealed that HPV infection was correlated with overall survival. This is the largest study to date to examine both p53 and HPV in patients with SCC of the head and neck. Our results suggest that HPV may be involved in the development of these cancers in patients without traditional risk factors and that HPV-related cancers are more prevalent in the white race.
Collapse
Affiliation(s)
- D J Haraf
- Department of Radiation, Section of Hematology, The University of Chicago, Illinois 60637, USA
| | | | | | | | | | | | | | | |
Collapse
|
35
|
Vokes EE, Dolan ME, Krishnasamy S, Mick R, Ratain MJ, Berezin F, Brachman D, Whitman G, Schilsky RL, Charette J. 5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: a clinical and pharmacologic analysis. Ann Oncol 1993; 4:591-5. [PMID: 8395874 DOI: 10.1093/oxfordjournals.annonc.a058594] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023] Open
Abstract
BACKGROUND Iododeoxyuridine (IUdR) is a known radiation enhancer, and interacts biochemically with 5-fluorouracil (5-FU) and hydroxyurea (HU). PATIENTS AND METHODS IUdR was added to the previously studied regimen of continuous infusion 5-FU at 300 mg/m2/day for 5 days, HU 500 mg every 12 hours for 11 doses and radiotherapy 200 cGy/day for 5 days, all administered for 7 consecutive weeks to patients with malignant glioma. IUdR was administered as 5-day continuous intravenous infusion during weeks 1 and 4. The IUdR dose was changed in cohorts of patients. IUdR plasma concentrations were determined during weeks 1 and 4, and IUdR incorporation into the DNA of granulocytes was measured on weeks 2 and 5. RESULTS Two patients treated at the initial IUdR dose of 500 mg/m2/day developed grade 3 or 4 myelosuppression and mucositis. Additional dose levels of IUdR tested were 250 mg/m2/day and 125 mg/m2/day; at the latter dose, severe or life-threatening toxicity was seen in only 3 of 8 patients treated. IUdR incorporation into DNA of granulocytes was 10.5(+/- 2.3)% at an IUdR dose of 500 mg/m2/day but decreased to 0.76(+/- 0.3)% at 125 mg/m2/day. Similarly, IUdR plasma concentrations decreased from 436 (+/- 114) ng/ml to 99 (+/- 29) ng/ml. CONCLUSIONS The addition of IUdR to 5-FU and HU results in significant systemic toxicity necessitating limitation of the IUdR dose to 125 mg/m2/day. There is a significant biochemical interaction between IUdR, 5-FU and HU leading to increased IUdR incorporation into DNA and to substantial clinical toxicity. Further clinical studies to exploit this interaction at more feasible schedules may be useful.
Collapse
Affiliation(s)
- E E Vokes
- Department of Medicine, University of Chicago, IL
| | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Vokes EE, Stupp R, Brachman D, Haraf D, McEvilly JM, Harris L, Luckett P, Weichselbaum RR. Intensified and accelerated concomitant chemoradiotherapy and G-CSF for locally advanced head and neck cancer. Eur J Cancer 1993. [DOI: 10.1016/0959-8049(93)91428-n] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
37
|
Haraf DJ, Kuchnir FT, Watson-Bullock S, Brachman D, Doughtery M, Rubin S, Sutton H. A dosimetric study comparing three-, four-, and six- field plans for treatment of carcinoma of the prostate. Med Dosim 1992; 17:191-8. [PMID: 1485906 DOI: 10.1016/s0958-3947(05)80003-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
We present a three-dimensional dosimetric analysis of 3-, 4-, and 6-field plans using 24 MV photon beams for treatment of carcinoma of the prostate. We compare isodose distributions on a transverse plane through the center of the target as well as differential and integral dose volume histograms for the target and critical structures, respectively. An extensive study on a representative case led to the development of a technique where two complementary 3-field daily plans deliver the same daily target dose as the standard 4-field box while affording sparing of the bladder and rectum similar to that achieved with a 6-field plan. This technique was shown to yield the same results on a sample of four additional patients representing a range of target and patient sizes. We conclude that the combined two-day, 3-field method for treatment of the prostate may be a better choice than the standard 4-field box or the 6-field daily plan for dose escalation studies.
Collapse
Affiliation(s)
- D J Haraf
- Department of Radiation and Cellular Oncology, University of Chicago, IL 60637
| | | | | | | | | | | | | |
Collapse
|